Back to search results
Active, not recruiting

Non-small Cell Lung Cancer

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC

JVCY | {{ defaultRegistry.registryAnchorText }} NCT02411448 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in participants with stage IV non small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in the first portion (Part A) before proceeding to the second portion of this study (Part B). The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC.

Time Commitment

You can participate in this study for as long as your study doctor determines is appropriate

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years
  • Participant must have diagnosis of Stage IV NSCLC

  • Participant must have documented evidence of a tumor with an activating EGFR mutation and be eligible for first-line treatment with erlotinib

  • Participant must be able to provide adequate archived Stage IV NSCLC tissue sample or tissue samples other than Stage IV NSCLC may be acceptable (optional for part C)

  • Participant must have ECOG performance status of 0 or 1 where 0 = Fully active, able to carry on all pre-disease performance without restriction and 1 = Restricted in physically strenuous activity but able to walk and carry out light work, e.g., light house work, office work

  • Participant must have one measurable lesion

  • Participant must not have a known T790M mutation

  • Participant must not have brain metastases

  • Participant must not have a history of significant bleeding disorders or blood clots in the arteries

  • Participant must not have any known significant abnormalities of the surface of the eye

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.